ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Information
About this company
Key people
Richard E. Lowenthal
President, Chief Executive Officer, Director
Kathleen D. Scott
Chief Financial Officer
Brian T. Dorsey
Chief Operating Officer
Justin Chakma
Chief Business Officer
Eric Karas
Chief Commercial Officer
Sarina Tanimoto
Chief Medical Officer
Alexander A. Fitzpatrick
Secretary and Chief Legal Officer
Pratik Shah
Chairman of the Board
Brenton L. Saunders
Director
Laura K. Shawver
Director
Rajeev Dadoo
Independent Director
Saqib Islam
Independent Director
Click to see more
Key facts
- Shares in issue98.85m
- EPICSPRY
- ISINUS82835W1080
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.00bn
- Employees162
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.